Clinical trials: Metastatic Colorectal Cancer (MCRC)
Colorectal Neoplasms, Metastatic Disease
Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab
The purpose of this study is to assess the efficacy of single-agent regorafenib in the second-line treatment in metastatic colorectal cancer with any RAS or BRAF mutation previously treated with FOLFOXIRI plus bevacizumab in…
- Trial name
- PREVIUM (NCT02175654)
- Testing
- Regorafenib
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Colorectal Neoplasms
Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)
The purpose of this study was to assess the preliminary antitumor activity, safety and tolerability of tepotinib in combination with cetuximab in participants with RAS/BRAF wild-type left-sided Metastatic Colorectal Cancer (mCRC)…
- Trial name
- NCT04515394
- Testing
- Tepotinib, Cetuximab
- Where
- 65 sites in United States, Belgium and 6 more
- Volunteers
- 3 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Metastatic Colorectal Cancer
Prospective Observational Study of 1st and 2nd Line Vectibix® Use in RAS-wt mCRC Pts to Evaluate Pattern of Use and ORR
The study will shed additional light on the impact of Vectibix® under the current, standard clinical conditions of mCRC treatment in Greece.
- Trial name
- VISION (NCT02322736)
- Where
- 20 sites in Greece
- Volunteers
- 218 people
- Sponsor
- Amgen
Colorectal Cancer Metastatic
ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC
The objective of this randomized controlled clinical trial is to evaluate the efficacy of ctDNA-guided rechallenge with cetuximab plus trifluridine/tipiracil compared with bevacizumab plus trifluridine/tipiracil in patients with…
- Trial name
- NCT07012954
- Testing
- Cetuximab (Erbitux, C225), trifluridine/tipiracil, Bevacizumab ( Avastin)
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Sun Yat-sen University
Metastatic Colorectal Cancer
Trifluridin/tipirACil in MeTastatIc Colorectal Cancer
A non-interventional, prospective, open, multicenter study in Germany in patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies and with…
- Trial name
- TACTIC (NCT03665506)
- Testing
- Trifluridin/Tipiracil
- Where
- Germany
- Volunteers
- 315 people
- Sponsor
- Servier
Metastatic Colorectal Cancer, Colorectal Cancer Metastatic
Sym004 Versus TAS-102 in Patients With mCRC
This is a Phase 3, randomized, open-label, 2-arm trial designed to evaluate overall survival (OS) following treatment with Sym004, an investigational medicinal product (IMP), versus TAS-102 (trifluridine/tipiracil), a comparator…
- Conditions
- Metastatic Colorectal Cancer, Colorectal Cancer Metastatic, Carcinoma
- Trial name
- NCT03717038
- Testing
- Sym004, TAS-102
- Sponsor
- Symphogen A/S
Metastatic Colorectal Cancer
Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC
NIPIRESCUE evaluates nivolumab and ipilimumab in patients with MSI/dMMR mCRC resistant to anti-PD1 monotherapy and previously treated with fluoropyrimidine, oxaliplatine, irinotecan, and anti- vascular endothelial growth factor…
- Trial name
- NIPIRESCUE (NCT05310643)
- Testing
- Nivolumab, Ipilimumab
- Where
- 9 sites in France
- Volunteers
- 30 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Advanced/Metastatic Colorectal Cancer
Combination of LTC004 and Regorafenib to Treat Patients With Advanced/Metastatic CRC
This is a phase II clinical study to evaluate the safety, tolerability and preliminary antitumor activity of LTC004 in combination with regorafenib in patients with mCRC.
- Trial name
- NCT06322563
- Testing
- LTC004+regorafenib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Colon Cancer, Rectal Cancer
CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC
This is a prospective, multicentre, cohort study. For cohort 1(CGA cohort), experimental cohort, older or Frail patients with metastatic colorectal cancer will receive Ultrafractionated Radiotherapy (RT) and Comprehensive…
- Trial name
- NCT06665087
- Testing
- Ultrafractionated RT and CGA Guided systemic treatment., Ultrafractionated Radiotherapy, PD-1 antibody
- Volunteers
- 110 people
- Sponsor
- Fudan University
Colorectal Cancer, RAS and BRAF Wild-type
Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients
This is an Open, Single Arm, Exploratory and Phase II Clinical Trial of Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF wild-type patients with Metastatic Colorectal Carcinoma(CRC) as 1st Therapy.
- Conditions
- Colorectal Cancer, RAS and BRAF Wild-type, Colorectal Neoplasms, Intestinal Neoplasms
- Trial name
- ALTER-C-002 (NCT04080843)
- Testing
- Anlotinib Hydrochloride, Capecitabine, Oxaliplatin
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Zhejiang University
Advanced or Metastatic Solid Tumors, Advanced or Metastatic Colorectal Cancer (mCRC)
First-in-human Study of CA102N Monotherapy and CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors
Study HS-CA102N-101 is a phase 1, two part (dose escalation, dose expansion), multicenter, non-randomized, open-label, multiple dose, first-in-human study of CA102N monotherapy and of CA102N combined with trifluridine/tipiracil…
- Trial name
- NCT03616574
- Testing
- CA102N, LONSURF
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- Holy Stone Healthcare Co., Ltd
Colorectal Cancer
Lohp, 5-Fu/Lv and Bevacizumab, Alternative With Cpt-11, 5-Fu/Lv and Cetuximab In Metastatic Crc
The aim of this study is to evaluate the efficacy of the effective drugs in a alternating chemotherapy schedules in pretreated patients with mCRC, who have received all effective drugs.
- Trial name
- NCT00755118
- Testing
- Oxaliplatin, 5-Fluorouracil, Leucovorin
- Where
- 3 sites in Greece
- Volunteers
- 24 people
- Sponsor
- University Hospital of Crete
Colorectal Cancer (CRC), Capecitabine
First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study
This multicenter, randomized, controlled, phase III study is conducted to evaluate the efficacy and safety of first line mCapOX plus Cetuximab versus mFOLFOX6 plus Cetuximab for RAS/BRAF wild-type, MSS, Unresectable Left-Sided…
- Conditions
- Colorectal Cancer (CRC), Capecitabine, Cetuximab
- Trial name
- CAPCET-III (NCT06616259)
- Testing
- mCapOX plus Cetuximab, mFOLFOX6 plus Cetuximab
- Where
- China
- Volunteers
- 452 people
- Sponsor
- Meng Qiu
Metastatic Colorectal Cancer
Trial of FOLF(HA)Iri With Cetuximab in mCRC
As an approach to improve efficacy and provide clinical benefit to cancer patients undergoing chemotherapeutic treatment regimens, Alchemia Oncology has developed a novel means for delivering anti-cancer agents to tumours.
- Trial name
- Chime (NCT02216487)
- Testing
- HA-Irinotecan
- Where
- 3 sites in Australia
- Volunteers
- 45 people
- Sponsor
- Western General Hospital, Australia
BRAF V600E Mutation Positive, Metastatic Colorectal Cancer
A Retrospective Non Interventional Study on First Line Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC)
The presence of a BRAFV600E mutation is considered a marker of poor prognosis in patients with mCRC, and findings from clinical trials have largely remained inconclusive regarding the efficacy of first line treatments for…
- Trial name
- CAPSTAN CRC (NCT04317599)
- Testing
- Non interventional
- Where
- 34 sites in Austria, Belgium and 5 more
- Volunteers
- 274 people
- Sponsor
- Pierre Fabre Medicament
Metastatic Colorectal Cancer, RAS Wild Type
Avelumab Plus Cetuximab in Pre-treated RAS Wild Type Metastatic Colorectal Cancer
This is a non-profit phase II, open-label, single-arm study of cetuximab plus avelumab in patients with RAS WT mCRC treated in first line with chemotherapy in combination with an anti- EGFR drug that have had a clinical benefit…
- Trial name
- NCT04561336
- Testing
- Avelumab, Cetuximab
- Where
- Italy
- Volunteers
- 77 people
- Sponsor
- University of Campania Luigi Vanvitelli
Metastatic Colorectal Cancer
Camrelizumab(SHR-1210) Combined With Apatinib in the Treatment of Advanced Metastatic Colorectal Cancer
The incidence and mortality of colorectal cancer in China's cancer disease spectrum is on the rise, and it is a common malignant tumor that harms the health of Chinese residents.This study was a one-arm, single-center, open…
- Trial name
- NCT03912857
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Intestinal Neoplasms, Gastrointestinal Neoplasms
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
The purpose of this study is to learn more about a new medicine called PF-08634404, and how well it works in people with cancer of the colon or rectum (CRC)).
- Conditions
- Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site
- Trial name
- NCT07222800
- Testing
- PF-08634404, Bevacizumab, Chemotherapy
- Where
- 372 sites in United States, Argentina and 15 more
- Volunteers
- 800 people
- Sponsor
- Pfizer
Metastatic Colorectal Cancer
Assessment of Clinical Practice Administration of Chemotherapy and Anti-angiogenic Agent (Bevacizumab) in Colorectal Cancer
Investigators propose to assess, retrospectively (from 1/7/2009) and prospectively (up to 31/12/2013,) the safety and tolerability profile (number of participants with adverse events) of standard chemotherapy and anti-angiogenic…
- Trial name
- NCT01811108
- Where
- 6 sites in Greece
- Volunteers
- 670 people
- Sponsor
- Hellenic Oncology Research Group
Liver Neoplasms, Colonic Neoplasms
Safety, Efficacy, and Dosing of Stereotactic Radiosurgery for Hepato-cellular Carc/Colo-rectal Liver Metastases
The purpose of this study is to determine a tolerable dose of radiation delivered by the CyberKnife system in two groups of patients with hepatocellular carcinoma (HCC).
- Conditions
- Liver Neoplasms, Colonic Neoplasms, Metastatic Cancer to Liver
- Trial name
- NCT01528878
- Testing
- Stereotactic Radiosurgery using the CyberKnife System.
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center